EcoDrugPlus

Receptor Activity Modifying Protein 1

Ensembl ID : ENSOKIG00005039951
Gene Symbol: RAMP1
1 Cross references
175 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSOKIG00005043346
Gene Symbol: RAMP1
1 Cross references
175 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSOKIG00005048750
Gene Symbol: LOC109867578
3 Cross references
185 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSOKIG00005006498
Gene Symbol: LOC109869292
3 Cross references
199 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSOKIG00005036889
Gene Symbol: LOC109878428
3 Cross references
199 Possible Orthologues:

Receptor-Interacting Serine/threonine-Protein Kinase 1

Ensembl ID : ENSOKIG00005027370
Gene Symbol: LOC109871759
3 Cross references
192 Possible Orthologues:

Receptor-Interacting Serine/threonine-Protein Kinase 1-Like

Ensembl ID : ENSOKIG00005029960
Gene Symbol: LOC109883234
3 Cross references
191 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSOKIG00005030841
Gene Symbol: RPTOR
3 Cross references
205 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSOKIG00005002010
Gene Symbol: RPTOR
3 Cross references
207 Possible Orthologues:

Renin

Ensembl ID : ENSOKIG00005034802
Gene Symbol: REN
3 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSOKIG00005006402
Gene Symbol: REN
3 Cross references
213 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A

Ensembl ID : ENSOKIG00005008370
Gene Symbol: LOC109868319
3 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).